IMRX News and Press, Immuneering Corporation From 09/28/23

2023-09-28 18:52:33 ET Summary Immuneering Corporation is developing novel small molecules for cyclical inhibition of MEK targets, but they are still in early development. Their first developmental project, IMM-1-104, has shown favorable pharmacokinetics and target inhibition in t...

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the ...

2023-08-03 18:01:05 ET Immuneering press release ( NASDAQ: IMRX ): Q2 GAAP EPS of -$0.43 beats by $0.08 . Cash, cash equivalents and marketable securities as of June 30, 2023 were $109.0 million, compared with $105.5 million as of December 31, 2022, and the c...

- Positive initial pharmacokinetic, pharmacodynamic and safety data presented at American Association for Cancer Research (AACR) annual meeting, with IMM-1-104 demonstrating Cmax, half-life, and pERK/pMEK suppression consistent with deep cyclic inhibition of the MAPK pathway - - Complet...

2023-07-07 17:55:10 ET Summary IMRX is an early-stage company with promising science. They do not have clinical efficacy data. While I like the company, be warned that this is going to take time. Two years ago, I covered Immuneering Corp ( IMRX ), then a preclini...

- No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during the Phase 1a dose escalation portion of ongoing clinical study - - Phase 1b dose expansion has commenced; plan to enroll 21 additional patients at 240 mg or 320 mg daily - - Recommended Phase 2 ...

CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Je...

2023-05-04 18:04:38 ET Immuneering press release ( NASDAQ: IMRX ): Q1 GAAP EPS of -$0.51 beats by $0.04 . Cash and cash equivalents and marketable securities as of March 31, 2023 were $91.5 million, compared with $105.5 million as of December 31, 2022. ...

- Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting - -First demonstration of novel deep cyclic inhibition mechanism in humans, with IMM-1-104 achievin...

2023-04-19 08:17:22 ET Shares of Immuneering Corporation ( NASDAQ: IMRX ) added ~8% pre-market Wednesday after Morgan Stanley and Mizuho upgraded the clinical-stage oncology company citing initial data for its lead candidate IMM-1-104. At the annual meeting of the American A...